Kadmon Holdings Inc (NYSE:KDMN) has been assigned a consensus rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $8.93.

KDMN has been the topic of a number of analyst reports. Oppenheimer initiated coverage on Kadmon in a research report on Wednesday, June 26th. They set an “outperform” rating and a $6.00 price target on the stock. ValuEngine raised Kadmon from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cantor Fitzgerald initiated coverage on Kadmon in a research report on Thursday, September 5th. They set an “overweight” rating and a $8.00 price target on the stock. Finally, Zacks Investment Research downgraded Kadmon from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th.

NYSE:KDMN traded down $0.09 during trading hours on Monday, reaching $2.83. 23,912 shares of the company were exchanged, compared to its average volume of 853,057. The company has a market capitalization of $362.33 million, a P/E ratio of -2.74 and a beta of 2.16. Kadmon has a 1-year low of $1.63 and a 1-year high of $3.82. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.99 and a quick ratio of 2.98. The business has a 50 day moving average of $2.44 and a 200 day moving average of $2.39.

Kadmon (NYSE:KDMN) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.03). The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.46 million. Kadmon had a negative return on equity of 96.96% and a negative net margin of 3,974.23%. As a group, equities research analysts anticipate that Kadmon will post -0.37 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of KDMN. Boxer Capital LLC acquired a new stake in shares of Kadmon in the 2nd quarter valued at $7,597,000. Vivo Capital LLC boosted its holdings in shares of Kadmon by 20.6% in the 1st quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock valued at $33,281,000 after purchasing an additional 2,152,060 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Kadmon by 23.5% in the 2nd quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after purchasing an additional 1,605,568 shares in the last quarter. Sofinnova Investments Inc. boosted its holdings in shares of Kadmon by 31.8% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,204,202 shares of the company’s stock valued at $4,540,000 after purchasing an additional 532,432 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Kadmon by 5.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock valued at $11,770,000 after purchasing an additional 320,710 shares in the last quarter. 77.04% of the stock is currently owned by hedge funds and other institutional investors.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: What are the qualifications of a portfolio manager?

Analyst Recommendations for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.